Parkinson Disease is a comprehensive introduction to the biology and clinical features of Parkinson disease (PD).
This book is aimed at clinicians in training, general neurologists seeking a useful guide to PD, and scientists seeking an overview of clinical aspects of PD.
Topics covered include nosology of PD, PD epidemiology, pathology and pathophysiology of PD, and theories of PD pathogenesis.
Clinical features, including the many non-motor features, natural history of disease progression, clinical pharmacology, and management of PD receive coverage.
Important themes are heterogeneity of PD, the multi-focal nature of PD pathology, the diversity of clinical features, dopaminergic signaling and the impacts of dopaminergic deficiency, the importance of non-motor features, limitations of existing treatment modalities, and the necessity of approaching PD as a multi-system disorder. The description and discussion of the many aspects of Parkinson disease (PD) is dogged by the fact that PD is an ambiguous concept. This book intends to be a useful overview, bridging the gap between general textbooks and specific topical reviews.
By:
Roger L. Albin ( University of Michigan)
Imprint: Oxford University Press Inc
Country of Publication: United States
Dimensions:
Height: 184mm,
Width: 259mm,
Spine: 24mm
Weight: 1g
ISBN: 9780190843014
ISBN 10: 0190843012
Series: CONTEMPORARY NEUROLOGY SERIES
Pages: 304
Publication Date: 05 January 2023
Audience:
Professional and scholarly
,
Undergraduate
Format: Hardback
Publisher's Status: Active
"Chapter 1: Definition, History, Nosology, and Classification Introduction and Definition Brief History of PD Nosology and Classification Scheme Classification Level 1 Classification Level 2 Ambiguities and Future Directions Conclusion Chapter 2: Epidemiology Introduction Prevalence Incidence Mortality Risk Factors Implications for Understanding Etiopathogenesis and the Future Burden of PD Chapter 3: Pathology Introduction The Aging Brain Gross Pathology, Lewy Pathology, and a-Synucleinopathy Substantia Nigra Pars Compacta Pathology Idiopathic Lewy Body Disease (iLBD) The Braak et al. Staging System Synucleinopathy Outside the Brain Non-Synuclein Pathologies Chapter 4: Pathophysiology I - Basal Ganglia Architecture and the Standard Model Introduction Basic Basal Ganglia Architecture The ""Standard"" Model of Basal Ganglia Pathophysiology Complexities of Basal Ganglia Architecture Conclusion Chapter 5: Pathophysiology II - Neurotransmitter System Dysfunctions Introduction Nigrostriatal Dopamine Signaling Functions Habit Formation and Chunking Cholinergic Projection System Dysfunctions Serotoninergic System Dysfunctions Conclusions and Future Challenges Chapter 6: Genetics of Parkinson Disease Introduction Dominant Forms of PD Recessive Forms of PD GBA PD Genetic Risk Factors Implications of PD Genetic Research Chapter 7: Pathogenesis Neuronal Vulnerability Alpha-Synuclein The Prion-Like Hypothesis Mitochondrial Dysfunction Oxidative Stress Endolysosomal Dysfunction Neuroinflammation Neuroprotection Trials Conclusions Chapter 8: Prodromal Parkinson Disease Introduction REM Sleep Behavior Disorder Observational Studies REM Sleep Behavior Disorder Cohort Studies Genetic Cohort Studies Autonomic Failure Future Directions Chapter 9: Clinical Features I - Initial Evaluation Presentation Features Nature of Diagnosis and Diagnostic Criteria History and Examination Differential Diagnosis Treatment Responsiveness Diagnostic Accuracy Chapter 10: Clinical Features II - Non-Motor Features Introduction Cognitive Impairments Neuropsychiatric Disorders Sleep Disorders Pain Fatigue Autonomic Disorders Visual Disorders Oral Health Conclusion Chapter 11: Clinical Features III - Natural History Introduction Assessing PD Progression PD Progression - Clinically Salient Features Subgroups Natural History Summary Continuing Care End of Life Care Chapter 12: Pharmacology I - L-Dopa Pharmacokinetics and Pharmacodynamics Introduction Dopaminergic Neurotransmission L-Dopa Pharmacokinetics L-Dopa Pharmacodynamics Peak Dose Dyskinesias Interactions of L-Dopa Pharmacokinetics, Pharmacodynamics, and Disease Progression Summary and Future Directions Chapter 13: Pharmacology II - Treating Parkinson Disease Introduction Using L-Dopa When the Honeymoon Is Over L-Dopa Adjuncts Dopamine Agonists Cholinergic Agents Other Symptomatic Therapies Future Directions Chapter 14: Surgery Introduction Deep Brain Stimulation: Rationale and Possible Mechanisms Deep Brain Stimulation: Procedures Deep Brain Stimulation: STN DBS Benefits Deep Brain Stimulation: GPi DBS Benefits and STN vs GPi DBS Deep Brain Stimulation: Adverse Events Lesional Procedures Cell-Based and Gene Therapies Future Directions Coda: Looking Ahead"
Roger L. Albin, M.D. is a graduate of Oberlin College and the University of Pittsburgh School of Medicine. He received clinical and post-doctoral training at the University of Michigan, where his mentors were Anne Young and the late Jack Penney. His primary research interest is the pathophysiology of basal ganglia disorders, including Parkinson disease, Tourette syndrome, and Huntington disease. He is presently Co-Director of the Parkinson Disease & Movement Disorders Division and Director of the Udall Center at the University of Michigan, and Associate Director for Research at the VAAAHS GRECC.
